Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

In today's culture, cannabis and its cannabinoids are used for both recreational and medicinal purposes. Patients are able to obtain medical and commercial cannabis products. Pharmacists should feel comfortable counseling their patients, given the increased interest, access, and use of these products. The objective of this survey was to assess the familiarity, attitudes, and knowledge of Wisconsin pharmacists regarding products containing cannabinoids. An anonymous, Web-based survey was administered to 511 Wisconsin pharmacists using the Pharmacy Practice Enhancement and Action Research Link. The survey was adapted from a nationally developed survey with established validity evidence. Survey items evaluated pharmacists' knowledge of the legality and the pharmacokinetic and pharmacodynamic properties of cannabis. The survey included knowledge (22 items), familiarity (14 items), and attitude (8 items) scales as well as pharmacist demographics and workplace type. Descriptive statistics, Fisher exact test, and Cronbach's alpha were calculated. The survey had a response rate of 19.3%. Nearly 75% of respondents were unfamiliar with the testing practices and pesticide regulations on cannabis production. Pharmacists were also unfamiliar with doses related to commercially available cannabinoid products. A quarter reported that they counsel at least monthly on cannabinoid therapies, but results showed that the majority are uncomfortable with the pharmacology and pharmacotherapy of these compounds. Over two-thirds reported that they need further education on cannabinoids and ranked continuing pharmacy education credits and webinars as their preferred method of learning. Over two-thirds at least somewhat agreed that they would feel comfortable recommending a Food and Drug Administration (FDA)-approved treatment, but a similar proportion reported that they would not recommend non-FDA approved cannabinoid treatments. Wisconsin pharmacists require more education to fill knowledge gaps regarding the therapeutic uses of cannabinoid products. Copyright Ā© 2021 American Pharmacists AssociationĀ®. Published by Elsevier Inc. All rights reserved.


Stephen Emmerling, Beth Martin, Natalie Schmitz. A survey of Wisconsin pharmacists about cannabinoid products: Are we ready to recommend? Journal of the American Pharmacists Association : JAPhA. 2021 Nov-Dec;61(6):e71-e75

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 34456146

View Full Text